[go: up one dir, main page]

Alauddin et al., 1999 - Google Patents

Evaluation of 9-[(3-18F-fluoro-1-hydroxy-2-propoxy) methyl] guanine ([18F]-FHPG) in vitro and in vivo as a probe for PET imaging of gene incorporation and …

Alauddin et al., 1999

View PDF
Document ID
3303262472120210899
Author
Alauddin M
Shahinian A
Kundu R
Gordon E
Conti P
Publication year
Publication venue
Nuclear medicine and biology

External Links

Snippet

Preparation of 9-[(3-18F-fluoro-1-hydroxy-2-propoxy) methyl]-guanine ([18F]-FHPG) for clinical use, and its evaluation as a positron emission tomography (PET) imaging agent for gene incorporation and expression in tumors are reported. In vitro studies in human colon …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Similar Documents

Publication Publication Date Title
Alauddin et al. Evaluation of 9-[(3-18F-fluoro-1-hydroxy-2-propoxy) methyl] guanine ([18F]-FHPG) in vitro and in vivo as a probe for PET imaging of gene incorporation and expression in tumors
Alauddin et al. Preclinical evaluation of the penciclovir analog 9-(4-[18F] fluoro-3-hydroxymethylbutyl) guanine for in vivo measurement of suicide gene expression with PET
US8101740B2 (en) Positron emission tomography probes for imaging immune activation and selected cancers
Waarde et al. Proliferation markers for the differential diagnosis of tumor and inflammation
Haberkorn et al. Ganciclovir uptake in human mammary carcinoma cells expressing herpes simplex virus thymidine kinase
Alauddin et al. In vivo evaluation of 2′-deoxy-2′-[18F] fluoro-5-iodo-1-β-D-arabinofuranosyluracil ([18F] FIAU) and 2′-deoxy-2′-[18F] fluoro-5-ethyl-1-β-D-arabinofuranosyluracil ([18F] FEAU) as markers for suicide gene expression
Haubner et al. In vivo imaging of herpes simplex virus type 1 thymidine kinase gene expression: early kinetics of radiolabelled FIAU
Shiue et al. A simplified one-pot synthesis of 9-[(3-[18F] fluoro-1-hydroxy-2-propoxy) methyl] guanine ([18F] FHPG) and 9-(4-[18F] fluoro-3-hydroxymethylbutyl) guanine ([18F] FHBG) for gene therapy
US5703056A (en) Non-invasive imaging of gene transfer
Zhang et al. Comparison of 18F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression
Kortylewicz et al. Radiolabeled cyclosaligenyl monophosphates of 5-iodo-2′-deoxyuridine, 5-iodo-3′-fluoro-2′, 3′-dideoxyuridine, and 3′-fluorothymidine for molecular radiotherapy of cancer: Synthesis and biological evaluation
Fuchigami et al. Synthesis and characterization of 9-(4-[18F] fluoro-3-(hydroxymethyl) butyl)-2-(phenylthio)-6-oxopurine as a novel PET agent for mutant herpes simplex virus type 1 thymidine kinase reporter gene imaging
Morin et al. Cytotoxicity and cellular uptake of pyrimidine nucleosides for imaging herpes simplex type-1 thymidine kinase (HSV-1 TK) expression in mammalian cells
Choi et al. SPECT Imaging of Herpes Simplex Virus Type1 Thymidine Kinase Gene Expression By [123I] FIAU1
Kim et al. Assessment of tumor cell proliferation using [18F] fluorodeoxyadenosine and [18F] fluoroethyluracil
Kortylewicz et al. Norepinephrine-transporter-targeted and DNA-co-targeted theranostic guanidines
Müller et al. Synthesis and evaluation of a C-6 alkylated pyrimidine derivative for the in vivo imaging of HSV1-TK gene expression
US20020025296A1 (en) Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy
AU715811B2 (en) Composition use of nucleoside analogues and gene transfection for tissue imaging and therapy
Chacko et al. Synthesis and in vitro evaluation of 5-[18F] fluoroalkyl pyrimidine nucleosides for molecular imaging of herpes simplex virus type 1 thymidine kinase reporter gene expression
I Wiebe et al. Biochemistry and biology of 2'-Fluoro-2'-deoxythymidine (FT), a putative highly selective substrate for thymidine kinase type 2 (TK2)
Alauddin et al. Biodistribution and PET imaging of [18F]-fluoroadenosine derivatives
Schipper et al. Evaluation of herpes simplex virus 1 thymidine kinase-mediated trapping of 131I fiau and prodrug activation of ganciclovir as a synergistic cancer radio/chemotherapy
Kim et al. Effects of structural differences between radioiodine-labeled 1-(2′-fluoro-2′-deoxy-d-arabinofuranosyl)-5-iodouracil (FIAU) and 1-(2′-fluoro-2′-deoxy-d-ribofuranosyl)-5-iodouracil (FIRU) on HSV1-TK reporter gene imaging
Alauddin et al. In vivo evaluation of 2 [variant prime]-deoxy-2 [variant prime]-[18F] fluoro-5-iodo-1-[beta]-D-arabinofuranosyluracil ([18F] FIAU) and 2 [variant prime]-deoxy-2 [variant prime]-[18F] fluoro-5-ethyl-1-[beta]-D-arabinofuranosyluracil ([18F] FEAU) as markers for suicide gene expression